International Journal of Hematology

, Volume 76, Supplement 2, pp 132–138 | Cite as

Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura

  • Han-Mou Tsai
Update on Bleeding Disorders

Abstract

Thrombotic thrombocytopenic purpura, characterized by the presence of systemic hyaline thrombi in the arterioles and capillaries, is a potentially fatal disease that responds to plasma infusion or exchange. Recent studies have demonstrated that a metalloprotease in the normal plasma cleaves endothelial von Willebrand factor to a series of multimers. A deficiency of the protease, due to autoimmune IgG inhibitors or genetic mutations’, is detected in patients with thrombotic thrombocytopenic purpura. Positional cloning based on kindreds with a genetic deficiency of the protease and amino acid sequencing of the purified protein have identified the protease as a novel member of the ADAMTS (a disintegrin and metalloprotease with thrombospondin type 1 repeat) zinc metalloprotease family located on the long arm of chromosome 9. Mutations of the gene are detected in patients with the congenital form of thrombotic thrombocytopenic purpura. In the circulation, proteolysis of von Willebrand factor is critical in regulating vWF-platelet interaction. These advances in knowledge provide the basis for a rational approach to improving the diagnosis and treatment of thrombotic thrombocytopenic purpura.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: A hitherto undescribed disease.Proc NYPathol Soc. 1924;24:21–24.Google Scholar
  2. 2.
    Ridolfi RL, Bell WR., Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature.Medicine (Baltimore). 1981;60:413–428.CrossRefGoogle Scholar
  3. 3.
    Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.N Engl J Med. 1991;325:393–397.PubMedGoogle Scholar
  4. 4.
    Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic hrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.N Engl J Med. 1991;325:398–403.PubMedGoogle Scholar
  5. 5.
    Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic hrombocytopenic purpura in the United States--analysis of national mortality data, 1968–1991.Am J Hematol. 1995;50:84–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group.Ann Intern Med. 1995;122:569–572.PubMedGoogle Scholar
  7. 7.
    Bell WR. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning.Semin Hematol. 1997;34:134–139.PubMedGoogle Scholar
  8. 8.
    Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.N Engl J Med. 1982;307:1432–1435.PubMedGoogle Scholar
  9. 9.
    Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen.Thromb Res. 1985;38:467–479.CrossRefGoogle Scholar
  10. 10.
    Chow TW, Turner NA, Chintagumpala M, et al. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura.Am J Hematol. 1998;57:293–302.PubMedCrossRefGoogle Scholar
  11. 11.
    Tsai HM, Nagel RL, Hatcher VB, Seaton AC, Sussman II. The high molecular weight form of endothelial cell von Willebrand factor is released by the regulated pathway.Br J Haematol. 1991;79:239–245.PubMedCrossRefGoogle Scholar
  12. 12.
    Handin RI, Wagner DD. Molecular and cellular biology of von Willebrand factor.Prog Hemost Thromb. 1989;9:233–59.PubMedGoogle Scholar
  13. 13.
    Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.Proc Natl Acad Sci USA. 1990;87:6306–6310.PubMedCrossRefGoogle Scholar
  14. 14.
    Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma.Blood. 1994;83:2171–2179.PubMedGoogle Scholar
  15. 15.
    Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.Blood. 1996;87:4235–4244.PubMedGoogle Scholar
  16. 16.
    Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.Blood. 1996;87:4223–4234.PubMedGoogle Scholar
  17. 17.
    Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1.Blood. 1997; 89:1954–1962.PubMedGoogle Scholar
  18. 18.
    Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.Blood. 1996;88:2939–2950.PubMedGoogle Scholar
  19. 19.
    Slayter H, Loscalzo J, Bockenstedt P, Handin RI. Native conformation of human von Willebrand protein. Analysis by electron microscopy and quasi-elastic light scattering.J Biol Chem. 1995;260:8559–8663.Google Scholar
  20. 20.
    Gralnick HR, Williams SB, McKeown LP, et al. In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand’s disease.Proc Natl Acad Sci USA. 1985;82:5968–5972.PubMedCrossRefGoogle Scholar
  21. 21.
    Batlle J, Lopez Fernandez MF, Campos M, et al. The heterogeneity of type IIA von Willebrand’s disease: studies with protease inhibitors.Blood. 1986;68:1207–1212.PubMedGoogle Scholar
  22. 22.
    Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.N Engl J Med. 1998;339:1578–1584.PubMedCrossRefGoogle Scholar
  23. 23.
    Tsai HM, Lian EC. Antibodies to von Willebrand factorcleaving protease in acute thrombotic thrombocytopenic purpura.N Engl J Med. 1998;339:1585–1594.PubMedCrossRefGoogle Scholar
  24. 24.
    Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.Am J Med. 1989;87:9N-15N.PubMedCrossRefGoogle Scholar
  25. 25.
    Moake JL, Byrnes JJ, Troll JH, et al. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura.Blood. 1985;65:1232–1236.PubMedGoogle Scholar
  26. 26.
    Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.Ann Intern Med. 2000;132:794–799.PubMedGoogle Scholar
  27. 27.
    Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factorcleaving protease in thrombotic thrombocytopenic purpura.Clin Lab. 2001;47:387–392.PubMedGoogle Scholar
  28. 28.
    Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura.Am J Hematol. 2000;65:251–255.PubMedCrossRefGoogle Scholar
  29. 29.
    Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; Chronic thrombocytopenia due to its deficiency.Blood. 1960;16:943–957.PubMedGoogle Scholar
  30. 30.
    Upshaw JD Jr. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia.N Engl J Med., 1978;298:1350–1352.PubMedGoogle Scholar
  31. 31.
    Chintagumpala MM, Hurwitz RL, Moake JL, Mahoney DH, Steuber CP. Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission.J Pediatr. 1992;120:49–53.PubMedCrossRefGoogle Scholar
  32. 32.
    Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.Nature. 2001;413:488–494.PubMedCrossRefGoogle Scholar
  33. 33.
    Tang BL. ADAMTS: a novel family of extracellular matrix proteases.Int J Biochem Cell Biol. 2001;33:33–44.PubMedCrossRefGoogle Scholar
  34. 34.
    Sieron AL, Tretiakova A, Jameson BA, et al. Structure and function of procollagen C-proteinase (mTolloid) domains determined by protease digestion, circular dichroism, binding to procollagen type I, and computer modeling.Biochemistry. 2000;39:3231–3239PubMedCrossRefGoogle Scholar
  35. 35.
    Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor — cleaving protease.Blood. 2001;98:1654–1661.PubMedCrossRefGoogle Scholar
  36. 36.
    Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.Blood. 2001;98:1662–1666.PubMedCrossRefGoogle Scholar
  37. 37.
    Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?J Biochem (Tokyo). 2001;130:475–480.Google Scholar
  38. 38.
    Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.J Biol Chem. 2001;276:41059–41063.PubMedCrossRefGoogle Scholar
  39. 39.
    Tsai HM, Chandler WL, Sarode R, et al. Von Willebrand Factor and Von Willebrand Factor-Cleaving Metalloprotease Activity in Escherichia coli O157:H7-Associated Hemolytic Uremic Syndrome.Pediatr Res. 2001;49:653–659.PubMedCrossRefGoogle Scholar
  40. 40.
    Hunt BJ, Lammle B, Nevard CH, Haycock GB, Furlan M. von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome.Thromb Haemost. 2001;85:975–958.PubMedGoogle Scholar
  41. 41.
    Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.Blood. 2001;98:1765–1772.PubMedCrossRefGoogle Scholar
  42. 42.
    van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura.Blood. 1999;93:3798–3802.PubMedGoogle Scholar
  43. 43.
    Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy.Hematol J. 2001;2:292–299.PubMedCrossRefGoogle Scholar
  44. 44.
    Fontana S, Gerritsen HE, Hovinga JK, Furlan M, Lammle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease.Br J Haematol. 2001; 113:100–102.PubMedCrossRefGoogle Scholar
  45. 45.
    Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells, Molecules, and Diseases 2002 (in press).Google Scholar
  46. 46.
    Oleksowicz L, Bhagwati N, DeLeon-Fernandez M. Deficient activity of von Willebrand’s factor-cleaving protease in patients with disseminated malignancies.Cancer Res. 1999;59:2244–2250.PubMedGoogle Scholar
  47. 47.
    Moore JC, Hayward CP, Warkentin TE, Kelton JG. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.Blood. 2001;98:1842–1846.PubMedCrossRefGoogle Scholar
  48. 48.
    Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.Blood. 2001;98:2730–2735.PubMedCrossRefGoogle Scholar
  49. 49.
    Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF.Thromb Haemost. 1999;82:1382–1385.PubMedGoogle Scholar
  50. 50.
    Gerritsen HE, Turecek PL, Schwarz HP, Lammle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP).Thromb Haemost. 1999;82:1386–1389.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Han-Mou Tsai
    • 1
  1. 1.Division of HematologyMontefiore Medical Center and Albert Einstein College of Medicine BronxNew YorkUSA

Personalised recommendations